---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-25-000029"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2025-04-14T23:59:59+00:00"
generated_at: "2026-05-23T15:22:35.722591+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Neurogene raises BBA director nomination threshold to 14.9%, exchanges shares for prefunded warrants

## Summary
- BBA director nomination threshold raised from 12.5% to 14.9% of voting common stock via amendment to July 2023 letter agreement.
- Exchange agreement: 667,500 common shares swapped for prefunded warrants to buy 667,563 shares at $0.001 exercise price.
- Post-exchange: 14,262,066 common shares outstanding; 6,792,559 prefunded warrants outstanding.
- Prefunded warrants have 4.99% beneficial ownership limitation, adjustable up to 19.99% with 61 days' notice.
- Exchange expected to close April 14, 2025, exempt from registration under Section 3(a)(9).

## SEC filing metadata
- accession: 0001404644-25-000029
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2025-04-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000029/0001404644-25-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000029/ngne-20250414.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-25-000029
- JSON: https://secwatch.observer/filing/0001404644-25-000029.json
- Plain text: https://secwatch.observer/filing/0001404644-25-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.